Elisa Sarto

Elisa Sarto

Auto-generated profile, based on publicly available information

Elisa Sarto

Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2014 in Brain
Verified
Journal Article
Closed access
PDF file
VPViviana Pensato
Viviana Pensato
BCBARBARA CASTELLOTTI
BARBARA CASTELLOTTI
CGCinzia Gellera
Cinzia Gellera
DPDavide Pareyson
Davide Pareyson
CCClaudia Ciano
Claudia Ciano
CMCaterina Mariotti
Caterina Mariotti
Hereditary spastic paraplegias are a heterogeneous group of neurodegenerative disorders, clinically classified in pure and complex forms. Genetically, more than 70 different forms of spastic paraplegias have been characterized. A subgroup of complicate recessive forms has been distinguished for the presence of thin corpus callosum and white matter lesions at brain imaging. This group includes several genetic entities, but most of the cases are caused by mutations in the KIAA1840 (SPG11) and ZFYVE26 genes (SPG15). We studied a cohort of 61 consecutive patients with complicated spastic paraplegias, presenting at least one of the following features: mental retardation, thin corpus callosum and/or white matter lesions. DNA samples were screened for mutations in the SPG11 /KIAA1840, SPG15/ ZFYVE26, SPG21 /ACP33 , SPG35 /FA2H , SPG48 /AP5Z1 and SPG54 /DDHD2 genes by direct sequencing. Sequence variants were found in 30 of 61 cases: 16 patients carried SPG11/ KIAA1840 gene variants (26.2%), nine patients carried SPG15 /ZFYVE26 variants (14.8%), three patients SPG35 /FA2H (5%), and two patients carried SPG48/ AP5Z1 gene variants (3%). Mean age at onset was similar in patients with SPG11 and with SPG15 (range 11–36), and the phenotype was mostly indistinguishable. Extrapyramidal signs were observed only in patients with SPG15, and epilepsy in three subjects with SPG11. Motor axonal neuropathy was found in 60% of cases with SPG11 and 70% of cases with SPG15. Subjects with SPG35 had intellectual impairment, spastic paraplegia, thin corpus callosum, white matter hyperintensities, and cerebellar atrophy. Two families had a late-onset presentation, and none had signs of brain iron accumulation. The patients with SPG48 were a 5-year-old child, homozygous for a missense SPG48/ AP5Z1 variant, and a 51-year-old female, carrying two different nonsense variants. Both patients had intellectual deficits, thin corpus callosum and white matter lesions. None of the cases in our cohort carried mutations in the SPG21 /ACP33 and SPG54/ DDH2H genes. Our study confirms that the phenotype of patients with SPG11 and with SPG15 is homogeneous, whereas cases with SPG35 and with SPG48 cases present overlapping features, and a broader clinical spectrum. The large group of non-diagnosed subjects (51%) suggests further genetic heterogeneity. The observation of common clinical features in association with defects in different causative genes, suggest a general vulnerability of the corticospinal tract axons to a wide spectrum of cellular alterations. * Abbreviations : ALS : amyotrophic lateral sclerosis SNP : single nucleotide polymorphism SPG : spastic paraplegia

17 April 2016 in Brain
Verified
Journal Article
Open access
PDF file
MSMatthis Synofzik
Matthis Synofzik
KSKatrien Smets
Katrien Smets
MMMartial Mallaret
Martial Mallaret
DBDaniela Di Bella
Daniela Di Bella
CGConstanze Gallenmüller
Constanze Gallenmüller
PBPeter Bauer
Peter Bauer
Mutations in the synaptic nuclear envelope protein 1 ( SYNE1 ) gene have been reported to cause a relatively pure, slowly progressive cerebellar recessive ataxia mostly identified in Quebec, Canada. Combining next-generation sequencing techniques and deep-phenotyping (clinics, magnetic resonance imaging, positron emission tomography, muscle histology), we here established the frequency, phenotypic spectrum and genetic spectrum of SYNE1 in a screening of 434 non-Canadian index patients from seven centres across Europe. Patients were screened by whole-exome sequencing or targeted panel sequencing, yielding 23 unrelated families with recessive truncating SYNE1 mutations (23/434 = 5.3%). In these families, 35 different mutations were identified, 34 of them not previously linked to human disease. While only 5/26 patients (19%) showed the classical SYNE1 phenotype of mildly progressive pure cerebellar ataxia, 21/26 (81%) exhibited additional complicating features, including motor neuron features in 15/26 (58%). In three patients, respiratory dysfunction was part of an early-onset multisystemic neuromuscular phenotype with mental retardation, leading to premature death at age 36 years in one of them. Positron emission tomography imaging confirmed hypometabolism in extra-cerebellar regions such as the brainstem. Muscle biopsy reliably showed severely reduced or absent SYNE1 staining, indicating its potential use as a non-genetic indicator for underlying SYNE1 mutations. Our findings, which present the largest systematic series of SYNE1 patients and mutations outside Canada, revise the view that SYNE1 ataxia causes mainly a relatively pure cerebellar recessive ataxia and that it is largely limited to Quebec. Instead, complex phenotypes with a wide range of extra-cerebellar neurological and non-neurological dysfunctions are frequent, including in particular motor neuron and brainstem dysfunction. The disease course in this multisystemic neurodegenerative disease can be fatal, including premature death due to respiratory dysfunction. With a relative frequency of ∼5%, SYNE1 is one of the more common recessive ataxias worldwide.

4 December 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
LNLorenzo Nanetti
Lorenzo Nanetti
ESElisa Sarto
Elisa Sarto
ACAnna Castaldo
Anna Castaldo
SMStefania Magri
Stefania Magri
AMAlessia Mongelli
Alessia Mongelli
FTFranco Taroni
Franco Taroni

22 August 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MGMarta Gatti
Marta Gatti
SMStefania Magri
Stefania Magri
LNLorenzo Nanetti
Lorenzo Nanetti
ESElisa Sarto
Elisa Sarto
DBDaniela Di Bella
Daniela Di Bella
FTFranco Taroni
Franco Taroni

17 May 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
APAna Potic
Ana Potic
APAleksandra M. Pavlovic
Aleksandra M. Pavlovic
GUGraziella Uziel
Graziella Uziel
DKDusko Kozic
Dusko Kozic
JOJelena Ostojic
Jelena Ostojic
Franco TaroniFranco Taroni
Franco Taroni

27 September 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MCMarta Cozzi
Marta Cozzi
SMStefania Magri
Stefania Magri
BTBarbara Tedesco
Barbara Tedesco
GPGuglielmo Patelli
Guglielmo Patelli
VFVeronica Ferrari
Veronica Ferrari
Angelo PolettiAngelo Poletti
Angelo Poletti
Mutations targeting distinct domains of the neuron-specific kinesin KIF5A associate with different neurodegenerative/neurodevelopmental disorders, but the molecular bases of this clinical heterogeneity are unknown. We characterised five key mutants covering the whole spectrum of KIF5A-related phenotypes: spastic paraplegia (SPG, R17Q and R280C), Charcot-Marie-Tooth disease (CMT, R864*), amyotrophic lateral sclerosis (ALS, N999Vfs*40), and neonatal intractable myoclonus (NEIMY, C975Vfs*73) KIF5A mutants. CMT-R864*-KIF5A and ALS-N999Vfs*40-KIF5A showed impaired autoinhibition and peripheral localisation accompanied by altered mitochondrial distribution, suggesting transport competence disruption. ALS-N999Vfs*40-KIF5A formed SQSTM1/p62-positive inclusions sequestering WT-KIF5A, indicating a gain of toxic function. SPG-R17Q-KIF5A and ALS-N999Vfs*40-KIF5A evidenced a shorter half-life compared to WT-KIF5A, and proteasomal blockage determined their accumulation into detergent-insoluble inclusions. Interestingly, SPG-R280C-KIF5A and ALS-N999Vfs*40-KIF5A both competed for degradation with proteasomal substrates. Finally, NEIMY-C975Vfs*73-KIF5A displayed a similar, but more severe aberrant behaviour compared to ALS-N999Vfs*40-KIF5A; these two mutants share an abnormal tail but cause disorders on the opposite end of KIF5A-linked phenotypic spectrum. Thus, our observations support the pathogenicity of novel KIF5A mutants, highlight abnormalities of recurrent variants, and demonstrate that both unique and shared mechanisms underpin KIF5A-related diseases.